We offer a solution for patients
with Acquired Brain Injury (ABI)
Neuron Guard is an innovative SME founded in 2013 for the development and manufacturing of a medical device to deliver selective and portable cerebral targeted temperature management. We have implemented a comprehensive quality management system according to ISO 13485
Acute Brain Injury (ABI)
Acute Brain Injury (ABI) is the leading cause of long-term disability and mortality, with growing costs related to care, support and social assistance. There are more than 4M cases of ABI in North America and Europe every year, the cost for the acute care of the severe cases (over 9%) ranges from $15k to $35k per patient.
4,3 Million
Acquired Brain Injury admissions in EU and in North America
9,3%
Percentage of severe cases on total
โฌ 16K-34K
Avarage cost per patient
The market needs
Acquired Brain Injury (ABI) results in diverse consequences, spanning physical, cognitive, emotional, and social domains.
These can include physical weakness, memory problems, mood disorders, social isolation, educational and employment challenges, seizures, and financial burdens. Rehabilitation is key to improving the quality of life for those with ABI.
ABI leads to an expenditure of $335.5 billion globally
41% is spent the US and 26% in Europe, representing 5.2% of the total health care costs
Itโs management is one of greatest challenges of modern Emergency Medicine because of the scope of the consequences both on the short term and on the medium/long term, with a significant impact on clinical, social and economic factors.
CB240_Aurora
Neuron Guard has developed CB240_AURORA to deliver selective and portable cerebral targeted temperature management which reduces the complexity of the treatment and improves the ease of use, unlike total body cooling devices.
Portability
Our collar can be used directly on the site of the event and accompanies the patient through the treatment process.
Head targeted Hypothermia
By cooling the blood that flows to the head we reduce the temperature of the brain without affecting significantly
Adaptive Temperature control
Sensors and a smart temperature control enable a fine regulation of the brain temperature both in the cooling and rewarming phase.
Our unique advantages
Miniaturization and portability
Avoids dangerous fluctuations in temperature during transfer to diagnostics and surgery or transport
Precise temperature control
Adapts to the needs of the patient
Brain targeted
Use of collar to induce selective brain cooling will reduce systemic complications (i.e. pneumonia)
Easy to use
Easy to use interface, reduces the nursing workload covering a smaller area of the body
Affordable
Financial sustainability, usable on ambulances
๐๐ซ๐๐ข๐ง ๐ญ๐ข๐ฌ๐ฌ๐ฎ๐ ๐ฉ๐๐ซ๐๐ฎ๐ฌ๐ข๐จ๐ง ๐๐ฎ๐ซ๐ข๐ง๐ ๐ฉ๐ฎ๐ฅ๐ฆ๐จ๐ง๐๐ซ๐ฒ ๐๐ง๐๐๐ซ๐ญ๐๐ซ๐๐๐ญ๐จ๐ฆ๐ฒ – ๐๐ก๐ ๐ข๐ฆ๐ฉ๐๐๐ญ ๐จ๐ ๐๐จ๐ง๐ญ๐ซ๐จ๐ฅ๐ฅ๐๐ ๐ซ๐๐ ๐ข๐จ๐ง๐๐ฅ ๐๐จ๐จ๐ฅ๐ข๐ง๐
๐๐๐ฐ ๐๐ฅ๐ข๐ง๐ข๐๐๐ฅ ๐๐ฏ๐ข๐๐๐ง๐๐ ๐ฌ๐ฎ๐ฉ๐ฉ๐จ๐ซ๐ญ๐ข๐ง๐ ๐ญ๐๐ซ๐ ๐๐ญ๐๐ ๐๐ซ๐๐ข๐ง ๐ญ๐๐ฆ๐ฉ๐๐ซ๐๐ญ๐ฎ๐ซ๐ ๐ฆ๐๐ง๐๐ ๐๐ฆ๐๐ง๐ญ ๐ฐ๐ข๐ญ๐ก ๐จ๐ฎ๐ซ ๐๐๐ฏ๐ข๐๐ ๐๐๐๐๐_๐๐ฎ๐ซ๐จ๐ซ๐We are pleased to…
Medtech Neuron Guard taps Broletto to scout for majority investor
Neuron Guard, an Italian medical technology company, is seeking a majority investor to fuel its…
The world’s first study starts for brain-cooling collar
The worldโs first study to measure the effectiveness of a pioneeringย medical deviceย to treatย patients with traumatic…
A Novel Technology for Targeted Brain Temperature Management
We are thrilled to announce the publication of the first-in-human study on Neurocritical Care. Our…
Round di investimento da 1,2 milioni di euro per Neuron Guard, la pmi innovativa attiva nel settore della gestione della temperatura cerebrale e corporea in ambito medicale e sportivo
Modena, 4 novembre 2021 โ Neuron Guard SRL, societร modenese attiva nello sviluppo, produzione e…
Weโre the winners of the Seedcorn Funding Competition 2018 by NIHR Brain Injury MIC
Cambridge, 3 September 2018 โ We are delighted to announce that we are the winners of the Seedcorn…
The team
Enrico Giuliani
is one of the founders of Neuron Guard. He is a registered anaesthesiologist and intensive care specialist with an experience in experimental medicine and device development. He will be responsible for supervising the progress of the clinical and regulatory work and liaise with the technical team.
Mary Franzese
is one of the founders of Neuron Guard. She has joined the team in the early stage of its incubation because of her attention and competence in the field of management and accounting, becoming a key element for the implementation of the solution. After taking a MD in Economics at LIUC University in 2011, she has worked for 2 years a manager of a cooperative active in the healthcare field. This experience has given her the chance to interact with intitutional healthcare related partner, understanding the peculiar characteristics of this field. In 2014, she completed a Master in Entrepreneurship and Corporate Strategy (MISA Program) at SDA Bocconi School of Management.
Andrea Nofri
is a senior manager with International track record in the general management of electromechanical/electronic companies. He concieved and carried out industrial plans of corporate restructuring, leading the relevant union negotiation. He took part in the Management Buy Ouy (M.B.O.) of a medium size Company. He joined the team in 2018 thanks to his wide commercial experience both domestic and international in business-to-business and in sales network management, a solid knowledge of strategic and operative marketing, business development and company branch transfer, familiar with multicultural and high organization complexity needs. He has joined the company in 2020 and is leading the clinical development of the device.
Andrea Lavinio
is a Consultant in Neurosciences and Trauma Critical Care and Anaesthesia at the Cambridge University Hospitals and an Affiliated Assistant Professor, University of Cambridge. He has joined the company in 2020 and is leading the clinical development of the device. Dr Lavinio has led the first-in-human pilot trail and will be responsible for Tier 1 and Tier 2 trials.
Arnaud Kontchou Tenda
is a mechanic engineer who joined the team in 2021. He is responsible for the mechanical design and testing of our products. He is involved in the technical compliance activities to meet the regulatory requirements.
Leo Cantergiani
is the CEO of TecnoElettra Impianti Srl (https://www.tecnoelettra.net/), main technical partner of Neuron Guard. Thanks to his experience in high technology projects (F1, aerospace, military), he has coordinated the development of the latest version of the system and he has been responsible for the design and manufacture of the collar active elements and the collar control unit.